S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.89%)
MU   67.96 (-0.10%)
CGC   0.74 (-5.85%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.15 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Forecast, Price & News

$10.15
-0.22 (-2.12%)
(As of 05:37 PM ET)
Compare
Today's Range
$9.83
$10.36
50-Day Range
$10.26
$15.70
52-Week Range
$5.84
$17.02
Volume
469,768 shs
Average Volume
395,157 shs
Market Capitalization
$576.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.33

Phathom Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
129.9% Upside
$23.33 Price Target
Short Interest
Bearish
10.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of Phathom Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.07) to ($4.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

563rd out of 969 stocks

Pharmaceutical Preparations Industry

265th out of 452 stocks


PHAT stock logo

About Phathom Pharmaceuticals (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT Price History

PHAT Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Phathom Pharma Submits NDA To FDA For Vonoprazan To Treat Non-Erosive GERD
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Reflux Testing Products Global Market Report 2023
JonesTrading downgrades Impel Pharmaceuticals (IMPL) to a Hold
JonesTrading Keeps Their Buy Rating on Ovid Therapeutics (OVID)
JonesTrading Remains a Buy on Longboard Pharmaceuticals (LBPH)
Phathom Pharmaceuticals (NASDAQ: PHAT)
Stoke Therapeutics (STOK) Gets a Buy from Needham
See More Headlines
Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAT Company Calendar

Last Earnings
8/10/2023
Today
10/02/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAT
Fax
N/A
Employees
112
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+127.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-197,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.80) per share

Miscellaneous

Free Float
52,543,000
Market Cap
$583.90 million
Optionable
Not Optionable
Beta
0.56
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Ms. Terrie J. CurranMs. Terrie J. Curran (Age 54)
    Pres, CEO & Director
    Comp: $1.11M
  • Mr. David A. SocksMr. David A. Socks (Age 48)
    Co-Founder & Director
    Comp: $58.78k
  • Dr. Azmi Nabulsi M.D. (Age 63)
    M.P.H., Co-Founder & COO
    Comp: $815.21k
  • Ms. Molly Henderson CPA (Age 52)
    MBA, Chief Financial & Bus. Officer
    Comp: $671.27k
  • Mr. Aditya Kohli Ph.D. (Age 35)
    Co-Founder
  • Mr. Anthony J. Guzzo (Age 50)
    Chief Accounting Officer
  • Mr. Joseph Hand J.D.
    Chief Admin. Officer
  • Mr. Lawrence Miller Esq.
    J.D., Gen. Counsel & Sec.
  • Mr. Tom Harris
    Chief Devel. Sciences Officer
  • Dr. Eckhard Leifke M.D.
    Ph.D., Chief Medical Officer













PHAT Stock - Frequently Asked Questions

Should I buy or sell Phathom Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHAT shares.
View PHAT analyst ratings
or view top-rated stocks.

What is Phathom Pharmaceuticals' stock price forecast for 2023?

7 analysts have issued twelve-month price objectives for Phathom Pharmaceuticals' stock. Their PHAT share price forecasts range from $16.00 to $30.00. On average, they predict the company's stock price to reach $23.33 in the next year. This suggests a possible upside of 127.0% from the stock's current price.
View analysts price targets for PHAT
or view top-rated stocks among Wall Street analysts.

How have PHAT shares performed in 2023?

Phathom Pharmaceuticals' stock was trading at $11.22 at the beginning of 2023. Since then, PHAT shares have decreased by 8.4% and is now trading at $10.28.
View the best growth stocks for 2023 here
.

When is Phathom Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PHAT earnings forecast
.

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its earnings results on Thursday, August, 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.11.

What ETFs hold Phathom Pharmaceuticals' stock?

ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).

When did Phathom Pharmaceuticals IPO?

(PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Phathom Pharmaceuticals' stock symbol?

Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT."

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phathom Pharmaceuticals' stock price today?

One share of PHAT stock can currently be purchased for approximately $10.28.

How much money does Phathom Pharmaceuticals make?

Phathom Pharmaceuticals (NASDAQ:PHAT) has a market capitalization of $583.90 million. The company earns $-197,720,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis.

How many employees does Phathom Pharmaceuticals have?

The company employs 112 workers across the globe.

How can I contact Phathom Pharmaceuticals?

Phathom Pharmaceuticals' mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The official website for the company is www.phathompharma.com. The company can be reached via phone at 877-742-8466 or via email at ir@phathompharma.com.

This page (NASDAQ:PHAT) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -